Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
Graziano G, Delre P, Carofiglio F, Brea J, Ligresti A, Kostrzewa M, Riganti C, Gioè-Gallo C, Majellaro M, Nicolotti O, Colabufo NA, Abate C, Loza MI, Sotelo E, Mangiatordi GF, Contino M, Stefanachi A, Leonetti F. Graziano G, et al. Among authors: riganti c. Eur J Med Chem. 2023 Feb 15;248:115109. doi: 10.1016/j.ejmech.2023.115109. Epub 2023 Jan 13. Eur J Med Chem. 2023. PMID: 36657299
The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines.
Schirizzi A, Contino M, Carrieri L, Riganti C, De Leonardis G, Scavo MP, Perrone MG, Miciaccia M, Kopecka J, Refolo MG, Lotesoriere C, Depalo N, Rizzi F, Giannelli G, Messa C, D'Alessandro R. Schirizzi A, et al. Among authors: riganti c. Front Oncol. 2023 Feb 16;13:1129832. doi: 10.3389/fonc.2023.1129832. eCollection 2023. Front Oncol. 2023. PMID: 36874116 Free PMC article.
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition.
Ponzone L, Audrito V, Landi C, Moiso E, Levra Levron C, Ferrua S, Savino A, Vitale N, Gasparrini M, Avalle L, Vantaggiato L, Shaba E, Tassone B, Saoncella S, Orso F, Viavattene D, Marina E, Fiorilla I, Burrone G, Abili Y, Altruda F, Bini L, Deaglio S, Defilippi P, Menga A, Poli V, Porporato PE, Provero P, Raffaelli N, Riganti C, Taverna D, Cavallo F, Calautti E. Ponzone L, et al. Among authors: riganti c. Mol Cancer. 2024 May 16;23(1):105. doi: 10.1186/s12943-024-02010-1. Mol Cancer. 2024. PMID: 38755661 Free PMC article.
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition.
Kalla C, Ott G, Finotello F, Niewola-Staszkowska K, Conza GD, Lahn M, van der Veen L, Schüler J, Falkenstern-Ge R, Kopecka J, Riganti C. Kalla C, et al. Among authors: riganti c. Transl Oncol. 2024 May;43:101857. doi: 10.1016/j.tranon.2023.101857. Epub 2024 Feb 27. Transl Oncol. 2024. PMID: 38412661 Free PMC article.
Flvcr1a deficiency promotes heme-based energy metabolism dysfunction in skeletal muscle.
Mistretta M, Fiorito V, Allocco AL, Ammirata G, Hsu MY, Digiovanni S, Belicchi M, Napoli L, Ripolone M, Trombetta E, Mauri P, Farini A, Meregalli M, Villa C, Porporato PE, Miniscalco B, Crich SG, Riganti C, Torrente Y, Tolosano E. Mistretta M, et al. Among authors: riganti c. Cell Rep. 2024 Mar 26;43(3):113854. doi: 10.1016/j.celrep.2024.113854. Epub 2024 Feb 26. Cell Rep. 2024. PMID: 38412099 Free article.
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
Maione F, Oddo D, Galvagno F, Falcomatà C, Pandini M, Macagno M, Pessei V, Barault L, Gigliotti C, Mira A, Corti G, Lamba S, Riganti C, Castella B, Massaia M, Rad R, Saur D, Bardelli A, Di Nicolantonio F. Maione F, et al. Among authors: riganti c. Mol Oncol. 2024 Feb 13. doi: 10.1002/1878-0261.13595. Online ahead of print. Mol Oncol. 2024. PMID: 38348572 Free article.
278 results